Best of ASCO - 2014 Annual Meeting

 

Welcome

Hormone Receptor-Positive

Breast Cancer—Metastatic

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
18F-Fluoroestradiol (FES) and 18F-Fluorodeoxyglucose (FDG) PET imaging in lobular breast cancer.

Poorni Manohar

1063

A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.

Romualdo Barroso-Sousa

1068

A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.

Mitsuhiko Iwamoto

e13059

A pilot exploration of clinicopathologic features with solid papillary carcinoma of the breast.

Xu Yingchun

e13056

A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.

Toshimi Takano

1046

A real-world experience of palbociclib-induced adverse events in women with HR-positive/Her2-negative metastatic breast cancer.

Geoffrey Alan Watson

e13061

A review of phase 3 clinical trials of CDK4/6 inhibitor combination therapy in premenopausal women.

Denise A. Yardley

e13057

A systematic literature review of the clinical prognosis of HR+/HER2- advanced or metastatic breast cancer with and without PIK3CA mutation.

Elizabeth J Anderson

e13037

Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.

Patrick Neven

1002

Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.

Andrew David Seidman

1042

AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer.

Luc Dirix

TPS1109

Alteration in red cell indices during palbociclib therapy.

Susan Bal

e13031

Benefit of CDK 4/6 inhibition in less common breast cancer subsets: A U.S. Food and Drug Administration pooled analysis.

Jennifer J Gao

1024

BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.

Hope S. Rugo

TPS1107

CDK inhibitors in advanced HR+ Her 2- breast cancer: A systematic review and meta-analysis of randomized trials.

Carlo Messina

e13047

Clinical algorithm to predict who may benefit from CDK4/6 inhibitors in patients (p) with estrogen receptor positive and HER-2 negative (ER+/Her2-) metastatic breast cancer (MBC).

Eudald Felip-Falgàs

e13060

Clinical characteristics, demographics, and outcomes in hormone-receptor (HR+) positive metastatic breast cancer (MBC) patients treated with palbociclib.

Chrystal Ann Landry

e13027

Clinical features of breast cancer patients with bone marrow metastasis.

Jing Sun

e13028

Clinical outcomes in patients receiving palbociclib + fulvestrant as first line treatment for ABC/MBC in real world settings in the United States.

John Waller

e13041

Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.

Francois P. Duhoux

1050

Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).

Joyce O'Shaughnessy

TPS1106

Cyclin-dependent kinases 4 and 6 inhibitors in HR+/HER2- advanced breast cancer.

Ying Wang

e13048

Efficacy and safety of fulvestrant 500 mg in Chinese HR-positive, HER2-negative metastatic breast cancer patients: A real-world study.

Xiying Shao

e13046

Efficacy and safety of low-dose everolimus in Chinese HR-positive, HER2-negative metastatic breast cancer patients.

Xiying Shao

e13035

Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer.

Jean-Philippe Zurcher

e13052

Efficacy of abemaciclib, palbociclib and ribociclib among the older compared with younger women in HR-positive/HER2-negative, advanced breast cancer.

Thierry Landre

e13043

Efficacy of CDK 4/6 inhibitors in ER positive metastatic breast cancer: Systematic review and meta-analysis of randomized clinical trials.

Alessandra Gennari

e13040

Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).

Aditya Bardia

1004

EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD.

Mark E. Robson

1045

Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

Guy Heinrich Maria Jerusalem

1005

Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.

Annelieke Willemsen

1062

Exhausted CD8+ cells (Tex) to predict response to PD-1 therapy in estrogen receptor (+) hormone therapy resistant breast cancer predictive of response to immune checkpoint inhibitors after epigenetic priming.

Pamela N. Munster

1044

First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.

Gabriel N. Hortobagyi

1022

First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study.

Paolo Pronzato

e13032

G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary phase 1b results.

Iurie Bulat

1061

Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.

Nicholas C. Turner

1001

Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting.

Nicole Princic

1067

Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.

Peter A. Kaufman

1049

Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.

Sunil Verma

1060

Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.

Sara M. Tolaney

1048

Lasofoxifene efficacy in a mammary intraductal (MIND) xenograft model of ERα+ breast cancer.

Muriel Laine

e13054

Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2.

Howard A. Burris

1041

Measuring validity of response assessment in bone predominant metastatic breast cancer based on clinico-radiological evaluation: An Inter-observer study.

Gurdip Kaur Azad

e13055

Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.

Arielle Medford

1021

Mutation signature of patients with ER+ metastatic breast cancer who received endocrine therapy.

Fei Ma

1057

Neutropenia and response to single agent palbociclib.

Nicholas Patrick McAndrew

1043

Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.

Nadine M. Tung

1052

Outcome of everolimus based therapy in hormone receptor positive metastatic breast cancer patients after progression on palbociclib combination.

Ajay Dhakal

1064

PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.

Francois Clement Bidard

TPS1105

Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.

Erica L. Mayer

TPS1104

Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009).

Andres Forero-Torres

1040

Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.

Kevin Kalinsky

1058

Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial).

Yukinori Ozaki

TPS1110

Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis.

Naoto T. Ueno

1065

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

Jose Baselga

LBA1006

Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC).

Sarah-Jane Dawson

1055

Plasma cell-free DNA copy number analysis by low coverage whole genome sequencing to monitor breast cancer relapse in CA15-3 and CEA silent patients.

Wen-Ming Cao

e13036

Pneumocystis jirovecii pneumonia associated with everolimus: Incidence and risk factors.

Melina Boutin

e13058

Real world clinical outcomes of palbociclib in hormone receptor positive (HR+) metastatic breast cancer (MBC) patients.

Akaolisa Samuel Eziokwu

e13034

Real world data in luminal like de novo metastatic breast cancer following guidelines recommendations.

Fernando Pikabea

e13029

Real world treatment patterns and clinical outcomes associated with palbociclib combination therapy in Argentina: Results from the IRIS study.

Gavin Taylor-Stokes

e13026

Real-world dosing patterns among metastatic breast cancer patients initiating first line (1L) palbociclib (PAL) therapy.

Damion Nero

e13050

Real-World single centre experience with Palbociclib as first line treatment in Indian patients with metastatic breast cancer.

Amit Rauthan

e13030

RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole—Results of the first interim analysis.

Peter A. Fasching

1051

Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.

Dennis J. Slamon

1000

Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis.

Sara A. Hurvitz

1047

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.

Michelino DeLaurentiis

1056

Safety of limited dose modifications for palbociclib associated neutropenia in ER+ metastatic breast cancer.

Anthony Dominick

e13033

Sperm associated antigen 5 (SPAG5) as a predictor and monitor for response and distant relapse risk (DRR) to endocrine (ET) and chemo-therapies (CT) in oestrogen receptor positive (ER+) breast cancer (BC).

Tarek Mohamed Ahmed Abdel-Fatah

1066

Study TTC-352-101: Phase 1 study of TTC-352 in patients with metastatic breast cancer (BC) progressing on endocrine therapy.

Ruth O'Regan

TPS1108

The association of early toxicity and outcomes for patients treated with abemaciclib.

Hope S. Rugo

1053

The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received.

Adrienne Gropper Waks

1054

Toxicity and efficacy of Palbociclib with endocrine therapy of physician’s choice in fourth line and beyond for hormone receptor-positive HER2-negative advanced breast cancer: A single centre experience.

Nicolo Matteo Luca Battisti

e13039

Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.

Richard S. Finn

1023

Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study.

Alessia D'Alonzo

e13053

Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.

Sara M. Tolaney

1059